



Nurix Therapeutics to Present at the 30th Annual Piper Jaffray Healthcare Conference

November 21, 2018

SAN FRANCISCO, Nov 21, 2018 – Nurix Therapeutics, Inc., a private company discovering drugs that harness the body's natural process to control protein levels, today announced that Arthur Sands, M.D., Ph.D., chief executive officer, will present at the 30th Annual Piper Jaffray Healthcare Conference to be held on November 27-29, 2018 at the Lotte New York Palace in New York City.

PRESENTATION DETAILS:

Presentation Title: Nurix Corporate Overview

Date: Tuesday, November 27, 2018

Time: 12:50 – 1:10 p.m. ET

ABOUT NURIX THERAPEUTICS

Nurix discovers drugs that harness the body's natural process to control protein levels. Our drugs control ubiquitin E3 ligases, the key enzymes responsible for protein breakdown in human cells, as a unique therapeutic approach to treat a broad range of diseases. Our initial focus is on developing drugs as treatments for hematologic cancers and immune-mediated diseases including immuno-oncology therapeutics for cancer. Nurix was founded by internationally-recognized experts in ligase biology and immunology and is funded by leading life science investors Third Rock Ventures and The Column Group. In September 2015, Nurix and Celgene entered into a broad collaboration targeting protein homeostasis for next-generation therapies in oncology, inflammation and immunology. The company is headquartered in San Francisco, California. For more information, please visit <https://www.nurixtx.com>.

Media Contact

Sara Zerkovic

LifeSci Public Relations

Sara@lifescipublicrelations.com